Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.64 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.64 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.64 |
| ▸ | FAP | Q12884 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421528 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5204465 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5206797 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| Bromide SCHEMBL5202128 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5203805 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL5202315 | 0.86 | DPP4 (0.76) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL6754510 | 0.86 | DPP4 (0.76) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5207093 | 0.85 | DPP4 (0.74) | DPP4DPP8DPP9DPP7FAP | |
| Hydrochloric Acid SCHEMBL5202305 | 0.84 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL5206238 | 0.84 | DPP4 (0.73) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980322-B2 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| EP-2191824-B1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| EP-1671649-B1 | Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure | TAKEDA PHARMACEUTICAL (JP) | 2011-11-23 | — | — | EP | disclosed |
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | KOWALSKI JAMES | 2011-04-14 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| EP-2191824-A1 | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation | Novartis AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | KOWALSKI JAMES | 2010-01-28 | — | — | US | disclosed |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. | 2007-05-17 | — | — | US | disclosed |
| US-20070072810-A1 | Agent for treating diabetes | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| EP-1746086-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-01-24 | — | — | EP | disclosed |
| US-20060177509-A1 | Controlled release composition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1671649-A1 | REMEDY FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-20060039974-A1 | Sustained release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1607088-A1 | CONTROLLED RELEASE COMPOSITION | Takeda Pharmaceutical Company Limited (JP) | 2005-12-21 | — | — | EP | disclosed |
| EP-1537880-A1 | SUSTAINED RELEASE PREPARATION | Takeda Pharmaceutical Company Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | DPP4 3186/4885DPP8 3643/4885DPP9 3586/4885 |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | DPP4 2412/4885DPP8 2730/4885DPP9 1380/4885 |
| US-20110086096-A1 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION | MAST1, CACNG1, CMA1 | DPP4 267/4885DPP8 1048/4885DPP9 849/4885 |
| US-20070072810-A1 | Agent for treating diabetes | IAPP, DPP4, GLP1R | DPP4 2/4885DPP8 7/4885DPP9 8/4885 |
| US-20060039974-A1 | Sustained release preparation | DPP4, DPP7, DPP3 | DPP4 1/4885DPP8 5/4885DPP9 4/4885 |
| US-20070112059-A1 | CYANOPYRROLIDINE DERIVATIVES | DPP4, DPP9, DPP3 | DPP4 1/4885DPP8 7/4885DPP9 2/4885 |
| US-20100021539-A1 | Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation | MAST1, CMA1, SUCNR1 | DPP4 195/4885DPP8 907/4885DPP9 810/4885 |
| US-20060177509-A1 | Controlled release composition | ATP6AP1, NSF, ATP6V1G1 | DPP4 2445/4885DPP8 2848/4885DPP9 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.